Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France

Figures & data

Figure 1. Identification of lymphoma and controls population. Abbreviations. HL, Hodgkin Lymphoma; FL, Follicular Lymphoma; DLBCL, Diffuse Large B-Cell Lymphoma.

Table 1. Baseline characteristics according to lymphoma subgroups (HL and B-NHL).

	HL			FL			DLBCL
	Cases (n = 57)	Controls (n = 228)	p	Cases (n = 64)	Controls (n = 256)	p	Cases (n = 103)	Controls (n = 412)	p
Age (mean, (sd))	46.9 (19.0)	46.9 (19.0)	1	63 (13.2)	63 (13.2)	1	65.9 (16.1)	65.9 (16.1)	1
Gender (women, (%))	23 (40.4)	92 (40.4)	1	30 (46.9)	120 (49.6)	1	57 (55.3)	228 (55.3)	1
CCI (n, (%))
0	47 (82.5)	201 (88.2)	.172	41 (64.1)	204 (79.7)	.009	75 (72.8)	337 (81.8)	.084
1–2	7 (12.3)	23 (10.1)		18 (28.1)	43 (16.8)		20 (19.4)	57 (13.8)
3–4	1 (1.8)	3 (1.3)		3 (4.7)	9 (3.5)		5 (4.9)	15 (3.6)
⩾5	2 (3.5)	1 (0.4)		2 (3.1)	0 (0)		3 (2.9)	3 (0.7)
Management by Private	6 (10.5)			6 (9)			14 (13.5)
Death* (n (%))	3 (5.3)			4 (6.3)			17 (16.5)
Follow-up (mean, [Q1–Q3])	199 [155; 253]			419 [104; 860]			186 [126; 232]

Abbreviations. HL, Hodgkin Lymphoma; FL, Follicular Lymphoma; DLBCL, Diffuse Large B Cells Lymphoma; CCI, Charlson Comorbidity Index; p, p-value; *Death 3 months after the end of active treatment phase.

Table 2. Mean costs per patient of lymphoma cases, controls, and additional costs according to lymphoma.

	Inpatient stays	Medical visits	Medical acts	Paramedical acts	Medication	Medical equipments	Transportation	Productivity loss	Total
HL
Cases (n = 57)	3075 [2325; 4580]	26 [21; 35]	188 [140; 280]	36 [24; 57]	592 [449; 812]	15 [10; 25]	255 [192; 337]	499 [337; 671]	4690 [3845; 5981]
Controls (n= 228)	95 [38; 284]	11 [8; 18]	16 [12; 31]	7 [4; 13]	32 [22; 63]	7 [3; 17]	7 [2; 21]	35 [22; 61]	212 [142; 432]
ΔCost	2980	15	172	29	560	8	248	464	4478
p	<.001	<.001	<.001	<.001	<.001	.055	<.001	<.001	<.001
FL
Cases (n= 64)	3188 [2733; 3716]	26 [21; 32]	118 [96; 148]	27 [16; 54]	427 [302; 613]	21 [11; 58]	92 [66; 129]	200 [114; 318]	4101 [3591; 4731]
Controls (n= 256)	73 [46; 122]	18[14; 24]	24 [20; 31]	24[13; 45]	62 [48; 88]	9[6; 15]	3 [2; 9]	64 [36; 124]	281 [212; 395]
ΔCost	3115	8	94	3	365	12	89	136	3820
p	<.001	.027	<.001	.767	<.001	.182	<.001	.011	<.001
DLBCL
Cases (n= 103)	5999 [5400; 6849]	28[23; 35]	181 [152; 238]	63[46; 96]	908 [803; 1027]	30[21; 45]	244 [200; 304]	261 [176; 374]	7745 [7071; 8518]
Controls (n= 412)	68 [43; 113]	12[11; 14]	20 [18; 24]	23[14; 39]	50 [43; 64]	8 [5; 15]	5 [3; 8]	32 [18; 58]	219 [180; 273]
ΔCost	5931	16	161	40	858	22	239	229	7526
p	<.001	<.001	<.001	.002	<.001	.001	<.001	<.001	<.001

Abbreviations. HL, Hodgkin Lymphoma; FL, Follicular Lymphoma; DLBCL, Diffuse Large B Cells Lymphoma; p, p-value.

Table 3. Gamma multivariate regression model on additional cost of lymphoma.

Variable	RR	CI (95%)	p
Age
[18; 55]	1
[56; 70]	1.00	[0.81; 1.24]	.983
[71; 89]	0.85	[0.68; 1.05]	.136
Gender
Female	1.01	[0.86; 1.19]	.869
Life State
Death	1.78	[1.37; 2.32]	<.001**
Place of management
Private	0.74	[0.57; 0.95]	.020*
Lymphoma subtype
FL	1
HL	1.11	[0.88–1.4]	.383
DLBCL	1.87	[1.53–2.28]	<.001**

Abbreviations. HL, Hodgkin Lymphoma; FL, Follicular Lymphoma; DLBCL, Diffuse Large B-Cell Lymphoma; RR, Relative Risk; p, p-value. *p < .05; **p < .001.